Brief: Destiny Pharma Announces Positive Update From US FDA On XF-73 Phase 3

Destiny Pharma

19/07/2022 07:20

July 19 (Reuters) - Destiny Pharma PLC  DEST.L :
    * DESTINY PHARMA PLC  - POSITIVE UPDATE FROM US FDA ON XF-73
PHASE
3
    * DESTINY PHARMA- FDA CLARIFIES PHASE 3 AND US REGISTRATION
PATHWAY FOR XF-73 NASAL GEL FOR PREVENTION OF POST-SURGICAL
STAPHYLOCOCCAL INFECTIONS

Source text for Eikon:  ID:nRSS8754Sa 
Further company coverage:  DEST.L 

 ((Reuters.Briefs@thomsonreuters.com;))